Le Lézard
Classified in: Health
Subjects: PER, MAT

Katie Mapel Takes the Helm as Director of Marketing for My Life's Simple/ReAction


MOORESVILLE, N.C., Nov. 19, 2019 /PRNewswire-PRWeb/ -- We are pleased and excited to officially welcome Katie Mapel to the My Lifes Simple/ReAction family as our new Director of Marketing. While there are several identified long term projects, objectives and strategies Katie will be working on, her initial focus and top priority will be the creation and implementation of a number of exciting, new Ambassador tools to help you build and grow your businesses.

She has extensive experience in the direct selling space, having spent 20 years with one of the largest and most successful direct selling companies in the world ? a company she helped grow from a six-year old company operating only in the U.S. to an established global brand in 26 countries across 5 continents. During her tenure, she championed for the distributor channel, designing and delivering countless award-winning programs and tools. Katie understands the unique challenges and opportunities of direct selling and the mindset of our Ambassadors, so we have no doubt you will see and feel the impact of her experience and expertise in your businesses very soon.

Katie had this to say about joining our team: "I grew up in direct selling, having spent my entire professional career in this industry. There is no other industry in the world like it, and no other industry I would rather commit my time and talents to. And there is no other company quite like yours. Your products, compensation plan and leadership are second to none. My Lifes Simple and ReAction are on track to transform both the direct selling and CBD industries, and I can't wait to be a part of it."

 

SOURCE My Life's Simple


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: